Science Explorer Interactive view Map
Company · Tokyo · Japan

SRL (Japan)

srl-group.co.jpROR OpenAlex
Research works
75
▲ 84% vs 2013–17
Citations
1.6k
21.8 per fractional work
Top-10% rate
9.6%
record average 16.5%
Open access
46%
world 28%

Not ranked overall: SRL (Japan) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Agricultural and Biological Sciences: 0.20× its world share, 0 worksAgricultural and Bio…Biochemistry, Genetics and Molecular Biology: 4.81× its world share, 4 worksBiochemistry, Geneti…Immunology and Microbiology: 5.40× its world share, 1 worksImmunology and Micro…Neuroscience: 1.77× its world share, 0 worksNeurosciencePharmacology, Toxicology and Pharmaceutics: 2.72× its world share, 0 worksPharmacology, Toxico…Engineering: 0.02× its world share, 0 worksEngineeringDentistry: 0.56× its world share, 0 worksDentistryMedicine: 3.31× its world share, 11 worksMedicine1×world share
more than its size predictsabout as predictedless

Rings at 0.5×, 1× and 2×. Widest outward: Immunology and Microbiology, 5.4×. Every wedge is a field page.

Which keywords describe research at SRL (Japan)?

By fractional works in all years, weighted toward what it does more of than the world: Chemotherapy, Targeted Therapy, Immunotherapy, Tumor Microenvironment, Prognostic Factors, Inflammation, Cancer and Cancer Genomics.

▲ more of its work than of the world’s◆ about the world’s share▼ less than the world’s

Size is fractional works in all years in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.

All 40 words, with their numbers
  1. Chemotherapy7▲ 13×12 topics
  2. Inflammation6▲ 3.5×21 topics
  3. Targeted Therapy6▲ 36×4 topics
  4. Epidemiology6▲ 1.90×28 topics
  5. Immunotherapy6▲ 11×12 topics
  6. Tumor Microenvironment5▲ 19×7 topics
  7. Cancer5▲ 4.6×20 topics
  8. Prognostic Factors4▲ 13×10 topics
  9. Oxidative Stress4▲ 2.7×10 topics
  10. Cancer Genomics4▲ 88×1 topic
  11. Mutational Signatures4▲ 88×1 topic
  12. Treatment4▲ 3.6×10 topics
  13. Clinical Trials3▲ 7.4×7 topics
  14. Molecular Characterization3▲ 23×3 topics
  15. Cancer Risk3▲ 15×3 topics
  16. Immune Response3▲ 6.2×10 topics
  17. Metabolism3▲ 6.1×8 topics
  18. Radiotherapy3▲ 10×5 topics
  19. Clinical Practice Guidelines3▲ 6.6×8 topics
  20. Biomarkers3▲ 5.8×7 topics
  21. Diagnosis3▲ 3.5×10 topics
  22. Immune Checkpoint Blockade2▲ 57×1 topic
  23. PD-1 and PD-L12▲ 57×1 topic
  24. Cancer Therapy2▲ 4.9×8 topics
  25. Gene Expression2▲ 5.1×9 topics
  26. Genetic Mutations2▲ 6.0×7 topics
  27. Liver Disease2▲ 22×3 topics
  28. Antiviral Therapy2▲ 20×3 topics
  29. Adjuvant Chemotherapy2▲ 39×2 topics
  30. Neoadjuvant Therapy2▲ 13×4 topics
  31. Genetic Testing2▲ 17×2 topics
  32. Hereditary Syndromes2▲ 71×1 topic
  33. Immunity2▲ 7.7×5 topics
  34. Microsatellite Instability2▲ 71×1 topic
  35. Pancreatic Cancer2▲ 21×2 topics
  36. Survival Analysis2▲ 9.5×5 topics
  37. Cetuximab2▲ 28×2 topics
  38. Precision Medicine2▲ 7.4×4 topics
  39. Therapeutic Targets2▲ 9.4×6 topics
  40. Genomic Profiling2▲ 22×2 topics

Which research topics does SRL (Japan) publish most on?

By volume in 2022–2025: Cancer Genomics and Diagnostics, Cancer Immunotherapy and Biomarkers, Pancreatic and Hepatic Oncology Research and Lung Cancer Research Studies.

Cancer Genomics and Diag…1Cancer Genomics and Diagnostics: 1 fractional worksCancer Immunotherapy and…1Cancer Immunotherapy and Biomarkers: 1 fractional worksPancreatic and Hepatic O…1Pancreatic and Hepatic Oncology Research: 1 fractional worksLung Cancer Research Stu…1Lung Cancer Research Studies: 1 fractional worksGenetics, Aging, and Longevity in Model Organisms: 1 fractional worksHepatocellular Carcinoma Treatment and Prognosis: 1 fractional worksImmunotherapy and Immune…0Immunotherapy and Immune Responses: 0 fractional worksGlioma Diagnosis and Treatment: 0 fractional worksProtein Hydrolysis and Bioactive Peptides: 0 fractional worksCircadian rhythm and mel…0Circadian rhythm and melatonin: 0 fractional works
Cancer ResearchOncologyAgingHepatology4 others

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 Cancer Genomics and Diagnostics Cancer Research 1 works
  2. 2 Cancer Immunotherapy and Biomarkers Oncology 1 works
  3. 3 Pancreatic and Hepatic Oncology Research Oncology 1 works
  4. 4 Lung Cancer Research Studies Oncology 1 works
  5. 5 Genetics, Aging, and Longevity in Model Organisms Aging 1 works
  6. 6 Hepatocellular Carcinoma Treatment and Prognosis Hepatology 1 works
  7. 7 Immunotherapy and Immune Responses Immunology 0 works
  8. 8 Glioma Diagnosis and Treatment Genetics 0 works
  9. 9 Protein Hydrolysis and Bioactive Peptides Molecular Biology 0 works
  10. 10 Circadian rhythm and melatonin Endocrine and Autonomic Systems 0 works

How open and international is its research?

Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available46.2%not open53.8%

World: 28% of research is openly available.

with international co-authors8.2%domestic only91.8%

World: 19% is written across borders.

How has SRL (Japan)'s research output changed?

Output in 2018–2022 was 84% higher than in 2013–2017.

1990200020102020
grewheldshrank

The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.

Other research institutions in Tokyo

All research institutions in Tokyo

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.